ACT 16116/2024

—·EP2493466: NOVEL ANTITUMORAL USE OF CABAZITAXEL

Case details: Status
—
Action
Infringement
Category
Main Infringement Action
Parties: Claimants
Sanofi SA (and related Sanofi entities)
Reps: Frédéric Chevallier (McDermott Will & Schulte)
Respondents
Accord Healthcare entities
STADAPHARM GmbH
STADA Arzneimittel AG
Reddy Pharma SAS
betapharm Arzneimittel GmbH
Zentiva France
Zentiva Pharma GmbH
Zentiva, k.s.
Reps: Jules Fabre (Taylor Wessing); Daniel Hoppe (Bonabry); Christian Meyer (Maiwald); Anja Lunze (Taylor Wessing)
Division: Munich LD
Judges: Matthias Zigann · Presiding Judge / Judge-Rapporteur
Technology: Pharmaceuticals · Oncology · Pharmaceutical & Medical
Language: —
First decided: Sep 15, 2025

Decisions

2025-09-15
Infringement Action
Procedural scheduling order by Munich Local Division (UPC_CFI_145-148/2024, 15 September 2025) summoning party experts to oral hearing on 14-17 October 2025 in four consolidated infringement proceedings by Sanofi entities against Accord Healthcare, STADA, Reddy Pharma/betapharm and Zentiva groups concerning EP 2 493 466.
Legal issues:Summons of party experts to oral hearing (R. 177.2, 181.1 RoP)Consolidated infringement actions

Documents